The global retinal disease therapeutics market, valued at USD 11,044.2 million in 2018, is anticipated to grow to USD 21,318.0 million by 2026, reflecting a compound annual growth rate (CAGR) of 8.6%. In 2018, North America led the global market, accounting for 36.6% of the total share.
The retinal disease therapeutics market focuses on the development and commercialization of treatments for various retinal disorders, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. These conditions can lead to vision impairment or blindness if left untreated, making early diagnosis and effective therapies crucial. The market encompasses a range of treatment options such as anti-VEGF drugs, corticosteroids, laser therapies, and emerging gene and cell-based therapies. Ongoing research, coupled with advancements in drug delivery systems and imaging technologies, continues to drive innovation in the field. As the global burden of retinal diseases increases, the demand for effective and accessible therapeutics is expected to grow significantly.
Continue reading for more details:
**https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311**
Retinal Disease Therapeutics Market Overview & Key Insights
Market Size & Forecast:
The global retinal disease therapeutics market was valued at USD 11,044.2 million in 2018 and is projected to reach USD 21,318.0 million by 2026, growing at a CAGR of 8.6% during the forecast period from 2018 to 2026.
Market Share Insights:
- Regional Landscape: In 2018, North America led the market with a 36.6% share, fueled by early regulatory approvals of innovative anti-VEGF therapies, a strong ophthalmic drug development pipeline, and high diagnosis and treatment rates across the region.
- By Disease Indication: Macular degeneration accounted for the largest share at 42.9% in 2018 and is expected to maintain its dominance through 2026. This is primarily attributed to the widespread prevalence of age-related macular degeneration (AMD) and the increasing availability of advanced diagnostic technologies.
Key Country Highlights:
- Japan: An aging population and proactive government-led awareness campaigns are encouraging the use of retinal therapies, particularly anti-VEGF treatments.
- United States: Market growth is driven by the widespread use and approval of therapies such as Eylea, Lucentis, and Avastin. High incidence rates of diabetic retinopathy and AMD continue to elevate the demand for treatment options.
- China: A surge in diabetes cases and increasing efforts for early detection of eye diseases are supporting the rapid expansion of the retinal therapeutics market.
- Europe: With over 34 million individuals affected by AMD across the EU, the region remains a key market. Strong reimbursement systems and well-established healthcare infrastructure are accelerating the adoption of novel therapies.
Market Segmentation
- By disease indication, the retinal disease therapeutics market is segmented into age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and others.
- Macular degeneration is expected to hold the dominant share due to high global prevalence and increased uptake of anti-VEGF treatments.
- By treatment type, the market includes anti-VEGF agents, corticosteroids, laser therapy, and gene therapies.